Adalimumab is a humanized recombinant monoclonal antibody fragment targeted against tumor necrosis factor. This study will assess the safety and efficacy of intravitreal adalimumab administered in patients with choroidal neovascularization secondary to age-related macular degeneration non-responders to the conventional treatment with intravitreal ranibizumab.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
Servicio de Oftalmologia. Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, Spain
Patients proportion with electroretinogram alterations
Time frame: 6 months
Changes in retinal thickness measured by ocular coherence tomography
Time frame: once a month to 6 months
Changes in best corrected visual acuity
Time frame: once a month to 6 months
Incidence of adverse events
Time frame: until 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.